Methenamine for urinary tract infection prophylaxis: A systematic review.
antiseptic
methenamine
prevention
prophylaxis
urinary tract infection
Journal
Pharmacotherapy
ISSN: 1875-9114
Titre abrégé: Pharmacotherapy
Pays: United States
ID NLM: 8111305
Informations de publication
Date de publication:
20 Nov 2023
20 Nov 2023
Historique:
revised:
27
10
2023
received:
31
08
2023
accepted:
30
10
2023
pubmed:
21
11
2023
medline:
21
11
2023
entrez:
21
11
2023
Statut:
aheadofprint
Résumé
Urinary tract infections (UTIs) commonly affect many patient populations. Recurrent UTIs (rUTIs) can be particularly problematic and lead to potential hospitalizations, multiple antibiotic courses, and have a potential negative impact on quality of life. To prevent UTIs, antibiotics are frequently used for prophylaxis; however, antibiotic prophylaxis has notable untoward consequences including but not limited to potential adverse effects and development of antibiotic resistance. Methenamine, an antiseptic agent initially available in 1967, has re-emerged as a potential option for UTI prophylaxis in various populations, including older adults and renal transplant recipients. The objective of this systematic review was to evaluate the clinical effectiveness and safety of methenamine for UTI prophylaxis. A systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidance was performed. A PubMed, Embase, and Cochrane library search was conducted to identify relevant English-language studies evaluating methenamine for UTI prophylaxis including randomized controlled trials, case-control studies, and meta-analyses through June 2023. Articles were excluded if the studies did not primarily describe or evaluate methenamine for UTI prophylaxis, were commentaries/viewpoints articles, point prevalence studies, review articles, studies that evaluated methenamine used with another agent, and any duplicate publications from searched databases. A total of 11 articles were identified for inclusion. This systematic review suggests methenamine generally appears to be an effective and well-tolerated antibiotic-sparing option for UTI prophylaxis. Furthermore, the pharmacology, dosage and formulation, warnings, precautions, and safety considerations of methenamine that provide potential clinical considerations regarding its use for UTI prophylaxis are described. Further studies are needed to evaluate the clinical utility of methenamine for UTI prophylaxis.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 Pharmacotherapy Publications, Inc.
Références
MacRae V, Holland S, MacLeod R. Diagnosing, managing and preventing urinary tract infections in older people with dementia in hospital. Nurs Older People. 2022;34(3):28-33.
Rowe TA, Juthani-Mehta M. Diagnosis and management of urinary tract infection in older adults. Infect Dis Clin North Am. 2014;28(1):75-89.
Snellings MS, Linnebur SA, Pearson SM, Wallace JI, Saseen JJ, Fixen DR. Effectiveness of Methenamine for UTI prevention in older adults. Ann Pharmacother. 2020;54(4):359-363.
Sihra N, Goodman A, Zakri R, Sahai A, Malde S. Nonantibiotic prevention and management of recurrent urinary tract infection. Nat Rev Urol. 2018;15(12):750-776.
Nicolle LE, Gupta K, Bradley SF, et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the infectious diseases Society of America. Clin Infect Dis. 2019;68(10):e83-e110.
Zare M, Vehreschild MJGT, Wagenlehner F. Management of uncomplicated recurrent urinary tract infections. BJU Int. 2022;129(6):668-678.
Medina M, Castillo-Pino E. An introduction to the epidemiology and burden of urinary tract infections. Ther Adv Urol. 2019;11:1756287219832172.
Langford BJ, Brown KA, Diong C, et al. The benefits and harms of antibiotic prophylaxis for urinary tract infection in older adults. Clin Infect Dis. 2021;73(3):e782-e791.
Fisher H, Oluboyede Y, Chadwick T, et al. Continuous low-dose antibiotic prophylaxis for adults with repeated urinary tract infections (AnTIC): a randomised, open-label trial. Lancet Infect Dis. 2018;18(9):957-968.
Jent P, Berger J, Kuhn A, Trautner BW, Atkinson A, Marschall J. Antibiotics for preventing recurrent urinary tract infection: systematic review and meta-analysis. Open Forum Infect Dis. 2022;9(7):ofac327.
Ahmed H, Davies F, Francis N, Farewell D, Butler C, Paranjothy S. Long-term antibiotics for prevention of recurrent urinary tract infection in older adults: systematic review and meta-analysis of randomised trials. BMJ Open. 2017;7(5):e015233.
Alberg T, Holen Ø, Blix HS, Lindbaek M, Bentele H, Eriksen HM. Antibiotic use and infections in nursing homes. Tidsskr nor Laegeforen. 2017;137(5):357-361.
PubChem [Internet]. National Library of Medicine (US), National Center for Biotechnology Information. PubChem Compound Summary for CID 21945, Methenamine hippurate. 2004 Accessed August 30, 2023. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Methenamine-hippurate
Chwa A, Kavanagh K, Linnebur SA, Fixen DR. Evaluation of methenamine for urinary tract infection prevention in older adults: a review of the evidence. Ther Adv Drug Saf. 2019;10:2042098619876749.
Lo TS, Hammer KDP, Zegarra M, Cho WCS. Methenamine: a forgotten drug for preventing recurrent urinary tract infection in a multidrug resistance era. Expert Rev Anti Infect Ther. 2014;12(5):549-554.
Hooton TM, Bradley SF, Cardenas DD, et al. Infectious Diseases Society of America. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(5):625-663.
Nahata MC, Cummins BA, McLeod DC, Schondelmeyer SW, Butler R. Effect of urinary acidifiers on formaldehyde concentration and efficacy with methenamine therapy. Eur J Clin Pharmacol. 1982;22(3):281-284.
Amneal Pharmaceuticals of New York LLC. Methenamine hippurate. [package insert]. U.S. Food and Drug Administration website. Accessed August 8, 2023. Available from: https://fda.report/DailyMed/4412d667-63f6-427e-a5c6-376a0e1e172d
MaCdougall C. Chapter 56, Sulfonamides, Trimethoprim-Sulfamethoxazole, Quinolones, and Agents for Urinary Tract Infections. In: Brunton LL, Hilal-Dandan R, Knollmann BC, eds. (Eds.)Goodman & Gilman's: the pharmacological basis of therapeutics. 13th ed. McGraw Hill; 2017 Accessed August 8, 2023. Available from: https://accesspharmacy.mhmedical.com/content.aspx?bookid=2189§ionid=172484698
Gleckman R, Alvarez S, Joubert DW, Matthews SJ. Drug therapy reviews: methenamine mandelate and methenamine hippurate. Am J Hosp Pharm. 1979;36(11):1509-1512.
Howard B. Methenamine. xPharm: the comprehensive pharmacology reference. Elsevier; 2007:1-4.
Hilal-Dandan R, Brunton LL, eds. Chapter 52, sulfonamides, trimethoprim-sulfamethoxazole, quinolones, and agents for urinary tract infections. In: (Eds.)Goodman and Gilman's Manual of Pharmacology and Therapeutics, 2e. McGraw Hill; 2016 Accessed August 11, 2023. Available from: https://accesspharmacy.mhmedical.com/content.aspx?bookid=1810§ionid=124495758
Musher DM, Griffith DP. Generation of formaldehyde from methenamine: effect of pH and concentration, and antibacterial effect. Antimicrob Agents Chemother. 1974;6(6):708-711.
Lexicomp®. Methenamine. Wolters Kluwer, Inc.; 2023 Accessed August 8, 2023. Available from: http://online.lexi.com
Cystex Plus™ (Methenamine, sodium salicylate) prescribing information [Internet]. Feasterville Trevose (PA): Clarion Brands, LLC. Accessed August 8, 2023. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=62200228-be42-1cda-9493-02bb491537c8
Urex™ (Methenamine hippurate) prescribing information [Internet]. Kirkland, Quebec, (CA): Draxis Pharma Inc. Accessed August 8, 2023. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/016151s025lbl.pdf
Hiprex® (methenamine hippurate) prescribing information [Internet]. Parsippany (NJ): Validus Pharmaceuticals LLC. Accessed August 8, 2023. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017681s018lbl.pdf
Methenamine mandelate prescribing information [Internet]. Parsippany (NJ): Edenbridge Pharmaceuticals LLC. Accessed August 8, 2023. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc299e8a-cf9a-4dc6-b6e6-972141e59296
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):89.
Lee BSB, Bhuta T, Simpson JM, Craig JC. Methenamine hippurate for preventing urinary tract infections. Cochrane Database Syst Rev. 2012;10(10):CD003265.
Bakhit M, Krzyzaniak N, Hilder J, Clark J, Scott AM, Del MC. Use of methenamine hippurate to prevent urinary tract infections in community adult women: a systematic review and meta-analysis. Br J Gen Pract. 2021;71(708):e528-e537.
Botros C, Lozo S, Iyer S, et al. Methenamine hippurate compared with trimethoprim for the prevention of recurrent urinary tract infections: a randomized clinical trial. Int Urogynecol J. 2022;33(3):571-580.
Rui L, Lindbaek M, Gjelstad S. Preventive effect of methenamine in women with recurrent urinary tract infections-a case-control study. Scand J Prim Health Care. 2022;40(3):331-338.
Harding C, Chadwick T, Homer T, et al. Methenamine hippurate compared with antibiotic prophylaxis to prevent recurrent urinary tract infections in women: the ALTAR non-inferiority RCT. Health Technol Assess. 2022;26(23):1-172.
Harding C, Mossop H, Homer T, et al. Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open label, randomised, non-inferiority trial. BMJ. 2022;376:e068229.
Heltveit-Olsen SR, Sundvall PD, Gunnarsson R, et al. Methenamine hippurate to prevent recurrent urinary tract infections in older women: protocol for a randomised, placebo-controlled trial (ImpresU). BMJ Open. 2022;12(11):e065217.
Hollyer I, Varias F, Ho B, Ison MG. Safety and efficacy of methenamine hippurate for the prevention of recurrent urinary tract infections in adult renal transplant recipients: a single center, retrospective study. Transpl Infect Dis. 2019;21(3):e13063.
Sweiss H, Bhayana S, Hall R, Nelson J, Kincaide E. Methenamine for recurrent urinary tract infections in solid organ transplantation. Prog Transplant. 2022;32(1):67-72.
Sauberan JB, Bradley JS. Antimicrobial Agents. Principles and practice of pediatric infectious diseases. Elsevier; 2018:1499-1531.e3.
Terlizzi ME, Gribaudo G, Maffei ME. UroPathogenic Escherichia coli (UPEC) infections: virulence factors, bladder responses, antibiotic, and non-antibiotic antimicrobial strategies. Front Microbiol. 2017;8:1566.
Peesa JP, Yalavarthi PR, Rasheed A, Mandava VBR. A perspective review on role of novel NSAID prodrugs in the management of acute inflammation. J Acute Dis. 2016;5(5):364-381.
Forbes R, Ali A, Abouhajar A, et al. ALternatives to prophylactic antibiotics for the treatment of recurrent urinary tract infection in women (ALTAR): study protocol for a multicentre, pragmatic, patient-randomised, non-inferiority trial. Trials. 2018;19(1):616.